双特异性抗体在多发性骨髓瘤中的演进 The evolution of bispecific antibodies in multiple myeloma. PubMed 2026/02/01 发表Chin Clin OncolQ3 · IF 2.7(JCR 2025) 靶点:CD20靶点:CD38靶点:BCMA技术:双特异性抗体多发性骨髓瘤B细胞淋巴瘤淋巴瘤
达雷妥尤单抗治疗 CD20(-)CD38(+) 复发/难治性弥漫大 B 细胞淋巴瘤 Daratumumab for CD20(-)CD38(+) Relapsed/Refractory Diffuse Large B-Cell Lymphoma. PubMed 2025/10/01 发表J Cell Mol MedQ2 · IF 4.7(JCR 2025) 靶点:CD20靶点:CD38技术:CAR-T弥漫大B细胞淋巴瘤淋巴瘤地区:中国
BNT162b2 mRNA 疫苗接种影响滤泡性淋巴瘤和慢性淋巴细胞白血病患者的肠道微生物组组成 BNT162b2 mRNA vaccination affects the gut microbiome composition of patients with follicular lymphoma and chronic lymphocytic leukemia. PubMed 2025/02/10 发表Biomark ResQ1 · IF 14.6(JCR 2025) 靶点:CD20靶点:CD38技术:NK 细胞技术:mRNA慢性淋巴细胞白血病滤泡性淋巴瘤淋巴瘤
解析 MYC 介导的对传统抗体与 T 细胞重定向治疗性抗体的逃逸机制 Delineating MYC-Mediated Escape Mechanisms from Conventional and T Cell-Redirecting Therapeutic Antibodies. PubMed 2024/11/11 发表Int J Mol SciQ1 · IF 5.6(JCR 2025) 靶点:CD19靶点:CD20靶点:CD38技术:NK 细胞技术:基因编辑技术:双特异性抗体
B 细胞恶性肿瘤新型治疗药物的现状:下一步是什么? Current Status of Novel Agents for the Treatment of B Cell Malignancies: What's Coming Next? PubMed 2022/12/07 发表Cancers (Basel)Q2 · IF 4.8(JCR 2025) 靶点:CD19靶点:CD20靶点:CD22技术:双特异性抗体B细胞淋巴瘤淋巴瘤白血病
唇腺间充质干细胞来源外泌体介导的 miRNA-125b 通过靶向 PRDM1 并抑制浆细胞减轻实验性干燥综合征 Labial Gland Mesenchymal Stem Cell Derived Exosomes-Mediated miRNA-125b Attenuates Experimental Sjogren's Syndrome by Targeting PRDM1 and Suppressing PubMed 2022/04/04 发表Front ImmunolQ1 · IF 7(JCR 2025) 靶点:CD19靶点:CD20靶点:CD38技术:间充质干细胞技术:外泌体B细胞淋巴瘤淋巴瘤
CD137 (4-1BB) 刺激导致人单核细胞/巨噬细胞代谢和功能重编程,增强其杀肿瘤活性 CD137 (4-1BB) stimulation leads to metabolic and functional reprogramming of human monocytes/macrophages enhancing their tumoricidal activity. PubMed 2021/05/21 发表LeukemiaQ1 · IF 8.8(JCR 2025) 靶点:CD20靶点:CD38多发性骨髓瘤淋巴瘤慢性淋巴细胞白血病地区:欧洲